At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
In Brief
A clinical study evaluating sildenafil, calcitonin, and 4 other interventions for Nephrogenic Diabetes Insipidus. Completed, enrolled 4 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).
Study Details
Timeline
Interventions
25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
one nasal spray daily for 4 days
25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
50 mg QD or 50 mg BID x 8 days depending on subject weight
one tablet daily for 4 days
one nasal spray daily